2026 Phi Delta Chi Grand Council

Briefly Debriefing: An Overview of Debriefing in Pharmacy Education and Practice

Debriefing, when done well, correlates with improvements in knowledge, skills, behaviors, and patient outcomes. However, the quality and consistency of debriefing practices vary widely. Facilitators often lack formal training in structured, evidence-based debriefing techniques and may miss opportunities for reflective learning. The purpose of this activity is to strengthen participants’ ability to conduct effective debriefings that promote critical reflection and clinical reasoning. This session will review essential elements of debriefing, including establishing a psychologically safe environment, using a stance of curiosity, and utilizing open-ended questions to explore models of thinking.

Objectives

Review debriefing and its applications in educational and practice settings
Identify strategies to strengthen feedback.
Review the essential element of the debriefing process.
Review the phases of the debriefing process.
Practice debriefing in a variety of scenarios.

Speaker(s)/Author(s)

Ethan Rawl

Activity Number

0064-9999-26-061-L04-P

Date: 07/30/26

Time: 01:00 AM - 01:00 AM

CE Hours

1.50

Timing of Immunization during Pregnancy and After Birth

Pharmacists need to know which vaccines to give or when to give them during pregnancy. Pharmacists would benefit from familiarity with this graphical guide that can help pharmacists more appropriately counsel and protect their pregnant patients.

Objectives

List the vaccine-preventable diseases that pregnant patients and their newborns are most susceptible to.
List the two ways to provide active immunity or passive immunity against respiratory syncytial virus (RSV).
(Given calendar month and gestational age), plan when influenza vaccine should be given to pregnant patient or infant.
(Given calendar month and gestational age), plan when Tdap should be given to pregnant patient or infant.
(Given calendar month and gestational age), plan when RSV vaccine or RSV monoclonal antibodies should be given to pregnant patient or infant.

Speaker(s)/Author(s)

COL (Ret) John Grabenstein

Activity Number

0064-9999-26-062-L06-P

Date: 07/30/26

Time: 01:00 AM - 01:00 AM

CE Hours

1.00

Introduction to Tensynoivial Giant Cell Tumors (TGCT)

Tenosynovial Giant Cell Tumor (TGCT) is a rare, locally aggressive joint neoplasm that causes chronic pain, joint destruction, and high surgical recurrence rates. The introduction of oral colony-stimulating factor 1 receptor (CSF1R) inhibitors has shifted management toward systemic targeted therapies; however, these medications carry significant black box warnings for severe hepatotoxicity and unique toxicity profiles. Pharmacists are uniquely positioned to help patients navigate these complexities, maximize therapy adherence, and improve quality of life. However, they frequently lack the specialized knowledge required to recognize this rare tumor type, interpret mandatory Risk Evaluation and Mitigation Strategies (REMS) criteria, manage medication adverse events, and advise patients on additional strategies to manage physical symptoms. Furthermore, pharmacists need education to effectively update healthcare providers on evolving treatment protocols and connect both providers and patients with available support resources.

Objectives

Describe differences and similarities between localized and diffuse TGCT.
List current treatment options for TGCT.
Identify barriers to care of patients.
Analyze strategies to educate providers and connect patients with available supportive care resources.
Review REMs requirements for applicable treatment.

Speaker(s)/Author(s)

Julie Carter

Activity Number

0064-9999-26-063-L01-P

Date: 07/31/26

Time: 01:00 AM - 01:00 AM

CE Hours

1.00

Clinical and Operational Frameworks for Gene Therapies in Specialty Pharmacy

The rapid expansion of cell and gene therapies presents a transformative shift in healthcare, yet many pharmacy professionals remain accustomed to traditional biologic workflows. Managing these high-cost pipeline therapeutics requires distinct operational frameworks, including ultra-cold chain logistics, and intensive patient access coordination. A clear gap in knowledge exists regarding the translation of clinical data into real-world operational readiness. The purpose of this knowledge-based activity is to bridge this gap by reviewing emerging gene therapy pipelines, addressing common distribution and reimbursement barriers, and outlining robust operational coordination models to optimize patient care and clinical safety.

Objectives

Identify key clinical characteristics, therapeutic mechanisms, and disease targets within the current and emerging cellular and gene.
Describe the distinct operational requirements for managing gene therapies, including ultra-cold chain logistics and product integrity.
Explain the administrative navigation required for patient access, including manufacturer REMS compliance and specialized reimbursement.
Review multi-disciplinary care coordination models designed to safely manage high-cost pipeline therapeutics within specialty pharmacy.

Speaker(s)/Author(s)

Will Griffith, Jr.

Activity Number

0064-9999-26-064-L01-P

Date: 07/31/26

Time: 01:00 AM - 01:00 AM

CE Hours

1.50

Psilocybin and Depression: Considering the evidence

Millions of Americans and people worldwide live with depression symptoms. For many, their symptoms remain resistant to treatment. Others experience barriers such as stigma, lack of education, and lack of access. While pharmacists cannot overcome all barriers, they are highly qualified to educate patients and reduce stigma. Psilocybin received BT status from the FDA to be studied for MDD/TRD and is predicted to be available either late 2026 or early 2027. Knowledge of current evidence-based treatments and how psilocybin therapy may change that landscape prepares pharmacists to better educate their patients. This knowledge-based activity will review diagnosis criteria, current treatment guidelines, patient barriers, psilocybin pharmacology, Pharmacodynamics, pharmacokinetics, and clinical data. Theoretically, it will help pharmacists better empathize with the patients that may need it most.

Objectives

Recognize the complexities for patients and clinicians navigating modern depression healthcare systems.
Review the current treatment recommendations for Major Depressive Disorder and Treatment Resistant Depression
Identify Barriers for patients seeking mental healthcare.
Cite current clinical evidence regarding psilocybin in Major Depressive Disorder and Treatment Resistant Depression
Translate increased depth of understanding to increased empathy in clinical practice.

Speaker(s)/Author(s)

Andy Krut

Activity Number

0064-9999-26-065-L08-P

Date: 08/01/26

Time: 01:00 AM - 01:00 AM

CE Hours

1.00

Pharmacy Benefit Managers: Understanding the System Behind the Prescription

Pharmacy Benefit Managers (PBMs) process the majority of all prescription claims in the United States yet remain poorly understood by many pharmacists. PBM business practices directly shape patient drug access, affordability, and outcomes. As federal and state regulatory scrutiny of PBMs intensifies, pharmacists who understand how these systems operate are uniquely positioned to advocate for patients through policy engagement, benefit design consultation, and business model innovation. The purpose of this knowledge-based activity is to review the structure and function of pharmacy benefit management, examine its implications for patient care, and identify opportunities for pharmacists to drive systemic improvement in drug access and outcomes.

Objectives

Describe the structure and function of pharmacy benefit managers (PBMs)
Explain how PBM business practices influence patient health outcomes
Identify the current regulatory landscape governing PBM practices
Recognize opportunities for pharmacists to engage with PBM-related advocacy
Apply knowledge of PBM mechanics to identify strategies for improving patient outcomes at the systems level.

Speaker(s)/Author(s)

Dillon Jerome Solliday

Activity Number

0064-9999-26-066-L04-P

Date: 08/01/26

Time: 01:00 AM - 01:00 AM

CE Hours

1.00

Student Research Showcase

In order to best practice evidence-based medicine, providers need to stay up to date with the results of new research. This program presents an examination of disparities in the management of Diabetes in African Americans, trends in Flu vaccination rates at Rutgers, and treatment options for acute headache in the Emergency Department.

Objectives

Identify gaps in outcomes from diabetes education for African American populations.
Recognize culturally adapted diabetes education interventions tailored to African American populations.
Describe the pathophysiology and common signs and symptoms of migraines.
Classify the pharmacology of dopamine antagonists.
Compare common emergency department treatment strategies for acute migraine episodes.
Define key metrics used in Rutgers University flu clinic data across a five-year time period.
List strategies used to improve accessibility and awareness of Rutgers University flu clinics.

Speaker(s)/Author(s)

An Nguyen
Calvin Van Mai
Chisom Ezenwenyi
Elizabeth Leoniuk
Evan Sisson
Jennifer Polyniak
Michael Reichert
Morgan Nguyen
Sarah Wheeler

Activity Number

0064-9999-26-067-L01-P

Date: 08/01/26

Time: 01:00 AM - 01:00 AM

CE Hours

1.00

Fee

CE Hours

CE Units

Activity Type

Target Audience(s)

Accreditation(s)